The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > REGULATORY
REGULATORY
- Keiya Iida of METI to Be First “Councilor for the Promotion of Pharmaceutical and Related Industries”: MHLW
July 8, 2014
- Kiyohito Nakai to Be Appointed Pharmaceutical Management Director
July 8, 2014
- Ryukaikon Council Member Requests Rewards instead of Penalties for Early Delivery Price Settlements
July 7, 2014
- Initiatives for Drug Distribution Improvement Advanced in FY2013: Ryukaikon Council
July 7, 2014
- Yuji Kanda to Head PFSB, Kazuo Futagawa to Head HPB Following Reshuffling of MHLW Top Officials
July 7, 2014
- MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
- MHLW to Require RMP Submissions around August for Generics of Blue Letter-Issued Original Drugs
July 2, 2014
- Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
- JPMA Official Calls for Partial Introduction of CDISC-Based Electronic Applications; Runup Period too Short
June 30, 2014
- Benefits of Electronic Applications to Be Shared by Patients, Companies, and Regulatory Authorities: MHLW Exec
June 30, 2014
- PAFSC’s Second Committee Supports Approval of IFN-Free Hepatitis C Treatments
June 30, 2014
- Chuikyo to Resume Discussions on Diovan Ads’ Impact on Healthcare Finances
June 27, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
- Govt Approves Economic Strategies, Chuikyo Likely to Discuss NHI Price Revision Frequency
June 25, 2014
- Ryukaikon to Meet on July 2; FY2013 Price Settlement Rates to Be Reported
June 25, 2014
- MHLW Issues Notification on Electronic Applications
June 24, 2014
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…